Winship Cancer Institute of Emory University | Strategic Alliance Partners

December 05, 2019

Sagar Lonial, MD, FACP, discusses important additions to the treatment arsenal in relapsed/refractory multiple myeloma.

December 04, 2019

Jonathon B. Cohen, MD, MS, discusses the integration of novel agents into clinical practice and the changing role of chemoimmunotherapy in chronic lymphocytic leukemia.

December 03, 2019

Jonathon B. Cohen, MD, MS, associate professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, co-director, Lymphoma Program, and medical director, Infusion Services, Winship Cancer Institute of Emory University, discusses the design of the phase III ELEVATE-TN trial in chronic lymphocytic leukemia (CLL).

November 21, 2019

Jonathon B. Cohen, MD, MS, discusses fixed-duration therapy in chronic lymphocytic leukemia.

November 16, 2019

Sagar Lonial, MD, FACP, discusses treatments for patients with heavily pretreated multiple myeloma.

November 16, 2019

Jonathon B. Cohen, MD, MS, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

November 14, 2019

Ajay K. Nooka, MD, MPH, FACP, discusses current options for transplant-eligible and -ineligible patients with multiple myeloma.

November 12, 2019

Keerthi Gogineni, MD, MSHP, discusses the clinical implications of the phase II APT trial in HER2-positive breast cancer.

November 12, 2019

Sagar Lonial, MD, FACP, discusses the management of patients with relapsed multiple myeloma.

October 31, 2019

Nabil F. Saba, MD, FACP, discusses the potential benefit of immunotherapy in combination with radiation in head and neck cancer.

October 31, 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, and professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses anticipated research in head and neck cancer.

October 16, 2019

In keeping up with the expanding breast cancer treatment armamentarium, we sat down with Jane L. Meisel, MD, and Aditya Bardia, MD, MPH, who shed light on emerging treatment strategies for patients with metastatic triple-negative breast cancer and discussed the optimal timing of genomic testing in women with progressive hormone receptor–positive disease.

October 16, 2019

Manali Bhave, MD, an assistant professor in the Department of Hematology and Medical Oncology at Winship Cancer Institute, Emory University School of Medicine, discusses promising anti-HER2 agents in metastatic HER2-positive breast cancer.

October 11, 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses ongoing research in head and neck cancer.

September 06, 2019

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the activity of osimertinib (Tagrisso) in combination with other agents in EGFR-mutant non–small cell lung cancer (NSCLC).

August 20, 2019

Suresh A. Ramalingam, MD, discusses recent updates in EGFR-mutant non–small cell lung cancer and the next steps for osimertinib and other agents in this patient population.

August 15, 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses investigational deintensification approaches in HPV-related oropharyngeal squamous cell carcinoma.

August 14, 2019

Keerthi Gogineni, MD, MSHP, an assistant professor in the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, discusses de-escalation strategies in HER2-positive breast cancer.

August 13, 2019

Rathi N. Pillai, MD, discusses the basis for frontline combinations of chemotherapy and immunotherapy in advanced nonsquamous non–small cell lung cancer and questions surrounding the optimal sequence of these agents.

August 13, 2019

Conor E. Steuer, MD, discusses emerging agents in the treatment of patients with ALK- or ROS1-positive non–small cell lung cancer and the sequencing challenges that have resulted in the space.